Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)

RCT (n=773) found, after achieving remission with 24 weeks ixekizumab treatment, those who withdrew to placebo had a reduced chance of remaining flare free after 400 weeks vs those on continued treatment (54.7% vs 83.3%, p<0.001).

Annals of the Rheumatic Diseases